Toralgen adds Ed Bastyr as Chief Medical Officer

INDIANAPOLIS, Indiana (April 28, 2021) – Toralgen, an Indiana-based biotechnology company focused on improving the delivery of biologics today announced the addition of Ed Bastyr III, MD to the newly created role of chief medical officer/clinical adviser.

Dr. Bastyr will oversee Toralgen’s clinical drug development, bringing more than 25 years of clinical drug development experience. “We are delighted to add Ed to our leadership team. His significant experience in clinical development is ideally suited to advance Toralgen into a clinical-stage company” said CEO, Gerald Rea.

Dr. Edward J Bastyr III work in science has taken him from basic bench research to clinical research in academic medicine and industry with the most recent 25 years dedicated to the pursuit of innovation in diabetes treatment, supporting both large pharma and smaller biotechnology companies. In various leadership roles at Lilly Research Laboratories (LRL), he was responsible for the development of several new molecular entities and was recognized by LRL with the President’s Recognition Award for Outstanding Scientific Achievement (Top 1% scientist Award) in 2002, 2009, and 2014. Subsequently he served as VP Medical at MB2, a small biotechnology company, where he developed unique peptides for the treatment of diabetes until the successful sale of the company and transfer of these peptides to Novo Nordisk. Dr. Bastyr is board certified by the American Board of Internal Medicine in Internal Medicine and Endocrinology Diabetes and Metabolism and is Associate Professor at Indiana University School of Medicine where his clinical responsibilities include the clinical training of the endocrinology fellows. Dr. Bastyr has published more than 150 abstracts and manuscripts in diabetes peer reviewed publications.

About Toralgen, Inc.
Toralgen, Inc. is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Its poly-bile nanoparticle platform eliminates many of the inherent challenges of biologics and has the potential to improve outcomes through optimized drug delivery. Toralgen is currently studying treatments for diabetes and autoimmune disorders. For information or to inquire about possible collaborations, visit our website.

Contact: Dave Moore, Toralgen,